Indeed, prostate carcinoma cells (LNCaP, DU145, PC3, LAPC4, C4-2) or other mammalian cancer cells (CHO, HEpG2, HEK293, CV-1, or MDA-MB-453 cells) that have been used for those screening campaigns strongly differ from their genetic backgrounds, in particular AR status, basal expression of other nuclear receptors, as well as AR cofactors [22,25,26,29,44,45,46,47]. This evidence concerns the gene AR and cancer.